Literature DB >> 22074424

A prodrug approach to improve the physico-chemical properties and decrease the genotoxicity of nitro compounds.

Man Chin Chung1, Priscila Longhin Bosquesi, Jean Leandro dos Santos.   

Abstract

In therapeutics research, the nitro compounds are part of an important group of drugs with multiple pharmacological activities. However, in drug design, the inclusion of a nitro group in a molecule changes the physico-chemical and electronic properties and is associated with increased mutagenicity and carcinogenicity. In addition, several studies have related the relationship between the antimicrobial and/or anti-protozoal activity and the mutagenic effect to reduction of the nitro group. This work reviews the toxicity of nitro compounds and shows how the use of prodrugs can increase the biological activity and decrease the genotoxicity of nitro compounds, without any modification in nitro reduction behavior, but rather by physico-chemical improvement. Examples are given of metronidazole and nitrofurazone prodrugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22074424     DOI: 10.2174/138161211798194512

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  13 in total

Review 1.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

2.  Ribonucleoside 3'-phosphates as pro-moieties for an orally administered drug.

Authors:  Michael J Palte; Amy K F Davis; Nicholas A McGrath; Carol A Spiegel; Ronald T Raines
Journal:  ChemMedChem       Date:  2012-07-13       Impact factor: 3.466

Review 3.  Recent Progress in the Synthesis of Drugs and Bioactive Molecules Incorporating Nitro(het)arene Core.

Authors:  Maxim Bastrakov; Alexey Starosotnikov
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-03

4.  Exploring N-acylhydrazone derivatives against clinical resistant bacterial strains.

Authors:  Andressa C Lannes; Bruno Leal; Juliana S Novais; Viviane Lione; Georgia C T S Monteiro; André L Lourenço; Plínio C Sathler; Alessandro K Jordão; Carlos R Rodrigues; Lúcio M Cabral; Anna Claudia Cunha; Vinicius Campos; Vítor F Ferreira; Maria Cecília B V de Souza; Dilvani O Santos; Helena C Castro
Journal:  Curr Microbiol       Date:  2014-05-08       Impact factor: 2.188

5.  Role of oxidative stress in the chemical structure-related genotoxicity of nitrofurantoin in Nrf2-deficient gpt delta mice.

Authors:  Takuma Tsuchiya; Aki Kijima; Yuji Ishii; Shinji Takasu; Yuh Yokoo; Akiyoshi Nishikawa; Tokuma Yanai; Takashi Umemura
Journal:  J Toxicol Pathol       Date:  2018-06-02       Impact factor: 1.628

6.  Mechanisms of oxidative stress-induced in vivo mutagenicity by potassium bromate and nitrofurantoin.

Authors:  Takuma Tsuchiya; Aki Kijima; Yuji Ishii; Shinji Takasu; Yuh Yokoo; Akiyoshi Nishikawa; Tokuma Yanai; Takashi Umemura
Journal:  J Toxicol Pathol       Date:  2018-06-02       Impact factor: 1.628

7.  Synthesis and antibacterial evaluation of New N-acylhydrazone derivatives from dehydroabietic acid.

Authors:  Wen Gu; Rongrong Wu; Shilong Qi; Chenhai Gu; Fanjunnan Si; Zhuhui Chen
Journal:  Molecules       Date:  2012-04-20       Impact factor: 4.411

Review 8.  Multidirectional Efficacy of Biologically Active Nitro Compounds Included in Medicines.

Authors:  Dorota Olender; Justyna Żwawiak; Lucjusz Zaprutko
Journal:  Pharmaceuticals (Basel)       Date:  2018-05-29

Review 9.  Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.

Authors:  Amjad M Qandil
Journal:  Int J Mol Sci       Date:  2012-12-17       Impact factor: 5.923

10.  Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo.

Authors:  C F Farias; M H Massaoka; N Girola; R A Azevedo; A K Ferreira; S D Jorge; L C Tavares; C R Figueiredo; L R Travassos
Journal:  BMC Cancer       Date:  2015-10-27       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.